Jonathan Rosenberg, MD
Enriched profileChief, Genitourinary Oncology Service, Division of Solid Tumor Oncology; Enno W. Ercklentz, Jr. Chair · Memorial Sloan Kettering Cancer Center
Jonathan Rosenberg is Chief, Genitourinary Oncology Service, Division of Solid Tumor Oncology; Enno W. Ercklentz, Jr. Chair at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 817 publications with 51,894 citations (h-index 85); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Jonathan Rosenberg as a Highly Cited Researcher (Cross-Field, 2021-2025).
Data verified 21 Sept 2026
Overview
Updated 14 Oct 2026
Jonathan Rosenberg, MD, is Chief, Genitourinary Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center. The public record shows 817 publications with 51,894 citations (h-index 85), centered on Prostate Cancer, Bladder / Urothelial Cancer. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 21 companies, 3 NIH-funded awards (2012–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Prostate Cancer
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Sponsor: Memorial Sloan Kettering Cancer Center
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 14 Oct 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202513 payments
- AstraZeneca UK LimitedProgram year20253 payments
- Samsung Bioepis Co., Ltd.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
52.2%Serotonin-3 Receptor Antagonist28.7%Ondansetron Hcl100%Part D≥13 patientsBiguanide (metformin)12.2%Metformin Hcl Er100%Part D<11 patients+ 1 more class in this area
Genitourinary & hormones
13.9%alpha-Adrenergic Blocker13.9%Tamsulosin Hcl100%Part D<11 patientsDermatology
13%Corticosteroid13%Triamcinolone Acetonide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
3 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Project 1: Elucidating Mechanisms of Sensitivity and Resistance to Combination Antibody-Drug Conjugate Therapy and Immunotherapy in Urothelial Cancer
Sloan-Kettering Inst Can Research
FY2026$499,767P50CA310825
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.
Clinical cancer research
Clinical Trial2026 - Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102).
JCO oncology advances
Article2026 - Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research.
JCO oncology practice
Article2026 - Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
CA: a cancer journal for clinicians
Article2026 - End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
Journal of clinical oncology
Article2025
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/Jonathan-E-Rosenberg-39327781
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/drrosenbergmsk
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/memorial-sloan-kettering-cancer-center_new-metastatic-bladder-cancer-therapy-approved-activity-7051906684356550656-eS8I
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
bcan.org/staff/jonathan-e-rosenberg-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org ↗ - Other
onclive.com/authors/jonathan-e-rosenberg-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - X / Twitter
x.com/MSKCancerCenter/status/1646181429351710720
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - BA
Duke University (undergraduate)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org ↗ - Internal Medicine residency/internship
NewYork-Presbyterian/Weill Cornell Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Medical Oncology (Hematology/Oncology) Fellowship
University of California San Francisco Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
- Chief
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Attending Physician
Memorial Hospital at Memorial Sloan Kettering Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org ↗ - Member
Scientific Advisory Board, Bladder Cancer Advocacy Network (BCAN)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Cross-Field20212022202320242025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Weill Cornell Medical College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗ - Prior faculty appointment
UCSF Comprehensive Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org ↗ - Prior faculty appointment
Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org ↗
Media & interviews
press, podcasts and appearances- Video roundup discussant
"Toni Choueiri and Jonathan Rosenberg Bladder Cancer Roundup," The ASCO Post
2018verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Contributing author/commentator
OncLive (bladder cancer / urothelial cancer coverage)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗
- Contributor
GU Oncology Now
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →guoncologynow.com ↗ - Author page / commentary contributor
Targeted Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)